Hormonal
Treatment with GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide produces substantial body weight loss (exceeding 15%) and improves glucose control, leading to type 2 diabetes prevention and possible disease remission.
If you have obesity or type 2 diabetes, GLP-1 receptor agonists (like semaglutide or liraglutide) are highly effective treatments that can help you lose more than 15% of your body weight and improve blood sugar control. This can potentially lead to remission of type 2 diabetes. While lifestyle changes are important, they are often not enough on their own to maintain weight loss or prevent diabetes progression, making these medications a key part of modern management.
Their use is associated with substantial and durable body weight reduction, exceeding 15%, and improved glucose control which further translate into T2D prevention, possible disease remission, and improvement of cardiometabolic risk factors and associated complications.
Why this rating
Based on multiple RCTs, meta-analyses, and expert group recommendations cited in the paper.
Source
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group
Andrej Janež et al. · Diabetes Therapy · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →